| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 39 | 2025 | 3123 | 3.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2024 | 1136 | 2.340 |
Why?
|
| Neoplasm Metastasis | 27 | 2024 | 1072 | 2.330 |
Why?
|
| Lung Neoplasms | 14 | 2024 | 2394 | 2.060 |
Why?
|
| Immunotherapy | 15 | 2025 | 725 | 1.960 |
Why?
|
| Radiosurgery | 11 | 2024 | 299 | 1.500 |
Why?
|
| Radiotherapy | 6 | 2025 | 324 | 1.430 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 621 | 1.240 |
Why?
|
| Mucin-1 | 9 | 2020 | 44 | 1.170 |
Why?
|
| Combined Modality Therapy | 19 | 2025 | 1733 | 1.140 |
Why?
|
| Radioimmunotherapy | 4 | 2024 | 27 | 1.010 |
Why?
|
| Biomarkers, Tumor | 8 | 2024 | 1573 | 0.990 |
Why?
|
| Liver Neoplasms | 8 | 2024 | 764 | 0.980 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2024 | 119 | 0.910 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 1308 | 0.890 |
Why?
|
| Aneuploidy | 1 | 2024 | 63 | 0.890 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 245 | 0.830 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 180 | 0.780 |
Why?
|
| Humans | 82 | 2025 | 92309 | 0.760 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 374 | 0.750 |
Why?
|
| Urinary Bladder | 1 | 2024 | 250 | 0.740 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 569 | 0.740 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 285 | 0.720 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 47 | 0.720 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 105 | 0.700 |
Why?
|
| Patient Care Team | 1 | 2023 | 296 | 0.700 |
Why?
|
| Homologous Recombination | 2 | 2017 | 53 | 0.630 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 1042 | 0.620 |
Why?
|
| Prostatic Neoplasms | 6 | 2024 | 1768 | 0.590 |
Why?
|
| Gene Amplification | 1 | 2018 | 137 | 0.560 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 58 | 0.560 |
Why?
|
| STAT1 Transcription Factor | 4 | 2009 | 54 | 0.550 |
Why?
|
| Pyrrolidines | 1 | 2018 | 60 | 0.550 |
Why?
|
| Anthracyclines | 1 | 2017 | 35 | 0.530 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 188 | 0.510 |
Why?
|
| Sulfonamides | 1 | 2018 | 327 | 0.480 |
Why?
|
| Breast Neoplasms | 7 | 2017 | 3054 | 0.470 |
Why?
|
| Cell Line, Tumor | 16 | 2024 | 2662 | 0.450 |
Why?
|
| MicroRNAs | 5 | 2023 | 573 | 0.440 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2024 | 27 | 0.430 |
Why?
|
| Drug Therapy | 1 | 2014 | 70 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 597 | 0.420 |
Why?
|
| Prognosis | 10 | 2021 | 3871 | 0.420 |
Why?
|
| Radiation Tolerance | 3 | 2019 | 174 | 0.410 |
Why?
|
| DNA Repair | 2 | 2022 | 367 | 0.410 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 521 | 0.410 |
Why?
|
| Mutation | 3 | 2024 | 4212 | 0.410 |
Why?
|
| Animals | 34 | 2025 | 28059 | 0.400 |
Why?
|
| Aged | 15 | 2024 | 19946 | 0.400 |
Why?
|
| Interferon Type I | 3 | 2024 | 195 | 0.390 |
Why?
|
| Radiation, Ionizing | 5 | 2021 | 124 | 0.390 |
Why?
|
| Mice | 21 | 2024 | 12133 | 0.350 |
Why?
|
| Capecitabine | 2 | 2024 | 92 | 0.350 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 354 | 0.340 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 433 | 0.340 |
Why?
|
| Signal Transduction | 10 | 2023 | 3504 | 0.330 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 1480 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 976 | 0.320 |
Why?
|
| Middle Aged | 15 | 2024 | 27038 | 0.320 |
Why?
|
| Survival Rate | 6 | 2024 | 1926 | 0.310 |
Why?
|
| Melanoma, Experimental | 3 | 2024 | 111 | 0.310 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 95 | 0.310 |
Why?
|
| Chemoradiotherapy | 3 | 2021 | 318 | 0.300 |
Why?
|
| Male | 20 | 2024 | 43917 | 0.300 |
Why?
|
| Female | 22 | 2024 | 47888 | 0.300 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2364 | 0.280 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 213 | 0.280 |
Why?
|
| RNA-Binding Proteins | 3 | 2024 | 284 | 0.280 |
Why?
|
| Energy Metabolism | 1 | 2009 | 302 | 0.270 |
Why?
|
| Gene Regulatory Networks | 2 | 2009 | 315 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2555 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2018 | 50 | 0.270 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6916 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1398 | 0.260 |
Why?
|
| Inflammation | 1 | 2012 | 1024 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 863 | 0.260 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 270 | 0.250 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 2032 | 0.250 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 139 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 501 | 0.240 |
Why?
|
| Mice, Nude | 5 | 2020 | 825 | 0.240 |
Why?
|
| Genomic Instability | 2 | 2017 | 85 | 0.240 |
Why?
|
| Brain Mapping | 1 | 2008 | 580 | 0.230 |
Why?
|
| DNA Replication | 2 | 2017 | 175 | 0.230 |
Why?
|
| Emotions | 1 | 2008 | 365 | 0.230 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.220 |
Why?
|
| Quality of Life | 2 | 2024 | 1745 | 0.220 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1761 | 0.220 |
Why?
|
| Telomerase | 1 | 2024 | 68 | 0.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 105 | 0.210 |
Why?
|
| Cognition | 1 | 2008 | 603 | 0.210 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 66 | 0.210 |
Why?
|
| Adult | 9 | 2024 | 27533 | 0.210 |
Why?
|
| Cystectomy | 1 | 2024 | 114 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 705 | 0.200 |
Why?
|
| DNA Methylation | 2 | 2018 | 678 | 0.200 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 23 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1398 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3776 | 0.190 |
Why?
|
| NF-kappa B | 2 | 2023 | 465 | 0.190 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 539 | 0.180 |
Why?
|
| Cisplatin | 1 | 2024 | 602 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 330 | 0.180 |
Why?
|
| Apoptosis | 5 | 2018 | 1737 | 0.180 |
Why?
|
| Light | 1 | 2022 | 295 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1720 | 0.180 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1241 | 0.180 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2023 | 9690 | 0.180 |
Why?
|
| Chemokine CXCL10 | 2 | 2024 | 22 | 0.170 |
Why?
|
| Dendritic Cells | 1 | 2024 | 478 | 0.170 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 1191 | 0.170 |
Why?
|
| Butyrates | 1 | 2021 | 53 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 3 | 2018 | 1045 | 0.170 |
Why?
|
| Pneumonia | 1 | 2022 | 187 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2024 | 8727 | 0.170 |
Why?
|
| Disease Progression | 3 | 2020 | 1500 | 0.170 |
Why?
|
| Cell Survival | 4 | 2019 | 1006 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 85 | 0.160 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 132 | 0.160 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 61 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 39 | 0.160 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 581 | 0.160 |
Why?
|
| DEAD Box Protein 58 | 2 | 2016 | 11 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 139 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 696 | 0.150 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 408 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 676 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 149 | 0.140 |
Why?
|
| Brain | 1 | 2008 | 2355 | 0.140 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 75 | 0.140 |
Why?
|
| Interferon-beta | 2 | 2016 | 126 | 0.140 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 195 | 0.140 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 96 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 262 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 236 | 0.130 |
Why?
|
| DNA Damage | 2 | 2017 | 381 | 0.130 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1279 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 98 | 0.130 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 69 | 0.130 |
Why?
|
| Adaptive Immunity | 3 | 2024 | 173 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 2450 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 3375 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 407 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2024 | 4471 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 696 | 0.120 |
Why?
|
| Biomarkers | 1 | 2022 | 1847 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 41 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 170 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 250 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 556 | 0.110 |
Why?
|
| RNA Helicases | 1 | 2014 | 35 | 0.110 |
Why?
|
| Prostate | 2 | 2020 | 413 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 65 | 0.100 |
Why?
|
| Mice, Knockout | 4 | 2024 | 2097 | 0.100 |
Why?
|
| Hospitalization | 1 | 2018 | 925 | 0.100 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 69 | 0.100 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2012 | 29 | 0.100 |
Why?
|
| Heterografts | 3 | 2018 | 107 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 245 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2012 | 471 | 0.090 |
Why?
|
| Ipilimumab | 2 | 2022 | 61 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2024 | 149 | 0.090 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 297 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 2 | 2012 | 151 | 0.090 |
Why?
|
| Myeloid Cells | 2 | 2023 | 107 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 456 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 168 | 0.090 |
Why?
|
| Interferon-gamma | 4 | 2019 | 454 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 401 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 995 | 0.080 |
Why?
|
| Glioma | 1 | 2012 | 305 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2023 | 102 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2024 | 314 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 105 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2024 | 441 | 0.080 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.080 |
Why?
|
| Interleukins | 1 | 2009 | 133 | 0.070 |
Why?
|
| Proteome | 1 | 2009 | 149 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3514 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 98 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 2 | 2018 | 20 | 0.070 |
Why?
|
| HCT116 Cells | 2 | 2018 | 159 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 117 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2900 | 0.070 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 398 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 361 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 215 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 377 | 0.060 |
Why?
|
| Recurrence | 1 | 2009 | 1180 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 628 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 547 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2016 | 265 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2025 | 72 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2025 | 120 | 0.060 |
Why?
|
| Leuprolide | 1 | 2024 | 35 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 172 | 0.050 |
Why?
|
| Etoposide | 1 | 2024 | 206 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2024 | 141 | 0.050 |
Why?
|
| Cell Movement | 2 | 2019 | 801 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1593 | 0.050 |
Why?
|
| Carboplatin | 1 | 2024 | 321 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 871 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 153 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 280 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 183 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 53 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2023 | 549 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 76 | 0.050 |
Why?
|
| Metastasectomy | 1 | 2020 | 9 | 0.040 |
Why?
|
| Vancomycin | 1 | 2021 | 73 | 0.040 |
Why?
|
| Synaptophysin | 1 | 2020 | 11 | 0.040 |
Why?
|
| POU Domain Factors | 1 | 2020 | 9 | 0.040 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 14 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 16 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2020 | 21 | 0.040 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2020 | 39 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 39 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 589 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 670 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2020 | 105 | 0.040 |
Why?
|
| Rats | 3 | 2010 | 4073 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 192 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2009 | 89 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2503 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 800 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 171 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 291 | 0.040 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2020 | 109 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 189 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 167 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 507 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 59 | 0.040 |
Why?
|
| Azacitidine | 1 | 2018 | 148 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 223 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 971 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 290 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 122 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 986 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 428 | 0.030 |
Why?
|
| cdc25 Phosphatases | 1 | 2016 | 19 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 500 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 475 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 763 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 49 | 0.030 |
Why?
|
| RNA, Small Untranslated | 1 | 2016 | 15 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 14 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 220 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 559 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 393 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 700 | 0.030 |
Why?
|
| Phenotype | 2 | 2015 | 2503 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1685 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1511 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2016 | 130 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1150 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 62 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 886 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 707 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2023 | 2006 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 206 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 277 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 1170 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 264 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1194 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 560 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 667 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 923 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 607 | 0.020 |
Why?
|
| Peptides | 1 | 2016 | 655 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 2368 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 31 | 0.020 |
Why?
|
| United States | 1 | 2025 | 7348 | 0.020 |
Why?
|
| Estradiol | 1 | 2012 | 250 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5428 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2014 | 276 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 234 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1312 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 390 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2685 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 341 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1606 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2009 | 24 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 232 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2009 | 16 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3206 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 87 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3806 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 284 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 33 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 157 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2009 | 171 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 341 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2012 | 479 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1512 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 443 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 689 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 296 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 887 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 807 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 740 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 369 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 273 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 900 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 785 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 460 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 462 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 1178 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2074 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 767 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3022 | 0.010 |
Why?
|
| Cytokines | 1 | 2009 | 842 | 0.010 |
Why?
|
| Child | 1 | 2016 | 7309 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 989 | 0.010 |
Why?
|
| Lung | 1 | 2009 | 1337 | 0.010 |
Why?
|